BioAtla, Inc.

    Jurisdiction
    United States
    ISIN
    US09077B1044 (BCAB)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €9.44M
    Gross margin
    99.0%
    EBIT
    -€54.72M
    EBIT margin
    -579.8%
    Net income
    -€51.06M
    Net margin
    -541.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 14, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 745K $258.31K -85K Sell

    Add to watchlist

    Notifications